Last updated on June 2019

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6


Brief description of study

The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective in randomized controlled clinical trials.

This observational study is an effectiveness research examining the regimen of GLE/PIB, used according to local label, under real world conditions in a clinical practice patient population.

Clinical Study Identifier: NCT03303599

Find a site near you

Start Over

Zna /Id# 170927

Antwerpen, Belgium
  Connect »

Hopital Saint Eloi /ID# 202512

Montpellier CEDEX 5, France
  Connect »

CHU Estaing /ID# 202949

Clermont Ferrand, France
  Connect »

CHU Nimes /ID# 208200

Nimes Cedex 9, France
  Connect »

Gastrodoc /Id# 206290

St Jean de Vedas, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.